摘要
慢性心力衰竭患者的交感神经系统具有较强的活性,随着病情的发展可引起心血管功能失常,具有较高的死亡率。β受体阻滞剂是一种强效、负性的肌力药,有很长一段时间被禁止用于慢性心力衰竭的临床治疗。但经大量的临床试验证明,β受体阻滞剂能够抑制神经内分泌活性以防止慢性心力衰竭患者的病情发展,对慢性心力衰竭的疗效是不可否认的。在我国,很多学者也紧随国际研究的步伐,开展了大量临床研究,本文针对β受体阻滞剂在慢性心力衰竭治疗的进展问题进行探讨性分析。
The sympathetic nervous system in the patients with chronic heart failure has strong activity, with the development of disease may cause cardiovascular dysfunction, which has a high mortality. Beta receptor blockers is a potent negative inotropic drugs, was been banned for clinical treatment of chronic heart failure for a long time. But large clinical trials proved that, beta receptor blockers can inhibit nerve endocrine activity in patients with chronic heart failure, so as to prevent the progression of the disease, the curative effect on chronic heart failure is undeniable. In China, many scholars also follow the international pace of research, carried out a large number of clinical researches. The objective of this paper is to explore and analysis beta receptor blockers in treating chronic heart failure..
出处
《中国继续医学教育》
2015年第7期247-248,共2页
China Continuing Medical Education
关键词
Β受体阻滞剂
慢性心力衰竭
研究进展
Beta receptor blocker
Chronic heart failure
Research progress
